Xamoterol: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A beta-1 adrenergic receptor partial agonist used in heart failure treatment}} | |||
== | == Xamoterol == | ||
[[File:Xamoterol.svg|thumb|right|Chemical structure of Xamoterol]] | |||
'''Xamoterol''' is a [[beta-1 adrenergic receptor]] partial agonist that has been used in the treatment of [[heart failure]]. It is known for its unique mechanism of action, which allows it to provide positive inotropic effects without significantly increasing heart rate. | |||
== | == Mechanism of Action == | ||
Xamoterol | Xamoterol acts as a partial agonist at the [[beta-1 adrenergic receptor]], which is primarily located in the heart. By partially stimulating these receptors, xamoterol increases the force of contraction of the heart muscle (positive inotropic effect) while having a minimal effect on heart rate. This makes it distinct from full agonists like [[isoproterenol]], which can cause significant increases in heart rate. | ||
== | == Clinical Use == | ||
Xamoterol has been used in the management of [[chronic heart failure]]. Its ability to enhance cardiac output without causing excessive tachycardia makes it a valuable option in certain patient populations. However, its use is limited compared to other heart failure medications such as [[ACE inhibitors]] and [[beta blockers]]. | |||
== | == Pharmacokinetics == | ||
Xamoterol is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The pharmacokinetic profile of xamoterol allows for convenient dosing schedules in the management of heart failure. | |||
== | == Side Effects == | ||
Common side effects of xamoterol include dizziness, headache, and fatigue. As with other medications affecting the cardiovascular system, there is a risk of arrhythmias, although this is less pronounced with xamoterol due to its partial agonist activity. | |||
[[ | == Related Pages == | ||
[[ | * [[Beta-adrenergic receptor]] | ||
[[ | * [[Heart failure]] | ||
* [[Inotropic agents]] | |||
* [[Adrenergic agonist]] | |||
[[Category:Beta-adrenergic agonists]] | |||
[[Category:Cardiovascular drugs]] | |||
Latest revision as of 04:00, 13 February 2025
A beta-1 adrenergic receptor partial agonist used in heart failure treatment
Xamoterol[edit]
Xamoterol is a beta-1 adrenergic receptor partial agonist that has been used in the treatment of heart failure. It is known for its unique mechanism of action, which allows it to provide positive inotropic effects without significantly increasing heart rate.
Mechanism of Action[edit]
Xamoterol acts as a partial agonist at the beta-1 adrenergic receptor, which is primarily located in the heart. By partially stimulating these receptors, xamoterol increases the force of contraction of the heart muscle (positive inotropic effect) while having a minimal effect on heart rate. This makes it distinct from full agonists like isoproterenol, which can cause significant increases in heart rate.
Clinical Use[edit]
Xamoterol has been used in the management of chronic heart failure. Its ability to enhance cardiac output without causing excessive tachycardia makes it a valuable option in certain patient populations. However, its use is limited compared to other heart failure medications such as ACE inhibitors and beta blockers.
Pharmacokinetics[edit]
Xamoterol is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The pharmacokinetic profile of xamoterol allows for convenient dosing schedules in the management of heart failure.
Side Effects[edit]
Common side effects of xamoterol include dizziness, headache, and fatigue. As with other medications affecting the cardiovascular system, there is a risk of arrhythmias, although this is less pronounced with xamoterol due to its partial agonist activity.
